PharmaShots | Incisive News in 3 Shots

Subscribe Now

All Posts by Date

PharmaShots Interview: Durect's James E. Brown Shares Insight on the Data of DUR-928 Presented at EASL 2021

PharmaShots Interview: Durect's James E. Brown Shares Insight on the Data of DUR-928 Presented at EASL 2021

September 20, 2021

Everest Enter into an Exclusive License Agreement with Sinovent and SinoMab to Develop and Commercialize XNW1011 for Renal Diseases

Everest Enter into an Exclusive License Agreement with Sinovent and SinoMab to Develop and Commercialize XNW1011 for Renal Disease...

September 20, 2021

Mirati Presents Results of Adagrasib (MRTX849) in P-I/II KRYSTAL–1 Study for the Treatment of KRAS G12C-Mutated Colorectal Cancer at ESMO 2021

Mirati Presents Results of Adagrasib (MRTX849) in P-I/II KRYSTAL–1 Study for the Treatment of KRAS G12C-Mutated Colorectal Cancer...

September 20, 2021

Regeneron and Sanofi Present Results of Libtayo (cemiplimab) in P-III EMPOWER-Lung 3 Study as 1L Treatment of Advanced NSCLC at ESMO 2021

Regeneron and Sanofi Present Results of Libtayo (cemiplimab) in P-III EMPOWER-Lung 3 Study as 1L Treatment of Advanced NSCLC at ES...

September 20, 2021

Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-826 Trial as 1L Treatment for Cervical Cancer

Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-826 Trial as 1L Treatment for Cervical Cancer

September 20, 2021

Exelixis' Cabometyx (cabozantinib) Receives the US FDA's Approval for the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Cancer

Exelixis' Cabometyx (cabozantinib) Receives the US FDA's Approval for the Treatment of Locally Advanced or Metastatic Differentiat...

September 20, 2021

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us